ArticleExploratory research in clinical and social pharmacy2026
SiMON-PRO-Hematology®: Digital techology for pharmacotherapeutic and patient reported outcomes monitoring in patients with hematologic malignancies.
Article in Exploratory research in clinical and social pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Advances in hematologic malignancy treatment have improved survival, but patients often experience treatment-related toxicities. Traditional clinical follow-up often overlooks the patient's subjective experience, highlighting the need for integrated patient-reported outcome measures (PROMs). The primary objective of this study was to describe the design and implementation of the SiMON-PRO-Hematology® system, a comprehensive information tool supporting the pharmacotherapeutic follow-up of patients with hematological malignancies. A secondary objective was to detail the process for PROM collection. Methods: SiMON-PRO-Hematology was designed by a multidisciplinary team of pharmacists, hematologists, nurses, and software engineers. This group defined the functional requirements of the system, as well as the demographic, clinical, laboratory, and pharmacotherapeutic variables and disease-specific PROMs relevant to hematologic malignancies. The system was structured into three main areas: Clinical care (assistance), management, and research. No primary data were collected; therefore, ethical approval was not required. Results: SiMON-PRO-Hematology automates PROM collection via tablet devices completed independently by patients. The platform integrates PROMs with baseline clinical data and laboratory results, generates real-time alerts, and supports structured pharmaceutical interventions. Business intelligence tools enable analysis of patient evolution, treatment adherence, and cohort comparisons. Implementation allows standardized, longitudinal follow-up, enhancing detection of safety and effectiveness signals while streamlining workflows and minimizing documentation duplication. Unlike existing tools, SiMON-PRO-Hematology integrates independently reported PROMs within a broader, adaptable monitoring system tailored to diverse hematologic malignancies. Discussion: This approach ilustrates how a fully integrated digital platform is designed to potentially enhance the quality and efficiency of pharmaceutical care, providing a technical framework to support proactive interventions, longitudinal monitoring, and patient-centered outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.